Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/S1473-3099(20)30282-6 http://scihub22266oqcxt.onion/10.1016/S1473-3099(20)30282-6 32563280!7302789!32563280     free     free     free Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Lancet+Infect+Dis 2020 ; 20 (9): e231-e237 Nephropedia Template TP {{tp|p=32563280|t=2020. Recent successes in therapeutics for Ebola virus disease: no time for complacency |pdf=|usr=}}{{32563280}} gab.com Text Recent successes in therapeutics for Ebola virus disease: no time for complacency JO: Lancet Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32563280 #FOAvip The PALM trial in the Democratic Republic of the Congo identified a statistically significant survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute Ebola virus disease; however, substantial gaps remain in improving the outcomes of acute Ebola virus disease and for the survivors. Ongoing efforts are needed to develop more effective strategies, particularly for individuals with severe disease, for prevention and treatment of viral persistence in immune-privileged sites, for optimisation of post-exposure prophylaxis, and to increase therapeutic breadth. As antibody-based approaches are identified and advanced, promising small-molecule antivirals currently in clinical stage development should continue to be evaluated for filovirus diseases, with consideration of their added value in combination approaches with bundled supportive care, their penetration in tissues of interest, the absence of interaction with glycoprotein-based vaccines, and filoviral breadth. Twit Text FOAVip Recent successes in therapeutics for Ebola virus disease: no time for complacency ????Lancet Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32563280 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32563280 #FOAvip English Wikipedia <ref>{{Cite pmid|32563280}}</ref> Recent successes in therapeutics for Ebola virus disease: no time for complacency #MMPMID32563280 Iversen PL; Kane CD; Zeng X; Panchal RG; Warren TK; Radoshitzky SR; Kuhn JH; Mudhasani RR; Cooper CL; Shurtleff AC; Nasar F; Sunay MM; Duplantier AJ; Eaton BP; Zumbrun EE; Bixler SL; Martin S; Meinig JM; Chiang CY; Sanchez-Lockhart M; Palacios GF; Kugelman JR; Martins KA; Pitt ML; Crozier I; Saunders DL Lancet Infect Dis 2020[Sep]; 20 (9): e231-e237 PMID32563280show ga The PALM trial in the Democratic Republic of the Congo identified a statistically significant survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute Ebola virus disease; however, substantial gaps remain in improving the outcomes of acute Ebola virus disease and for the survivors. Ongoing efforts are needed to develop more effective strategies, particularly for individuals with severe disease, for prevention and treatment of viral persistence in immune-privileged sites, for optimisation of post-exposure prophylaxis, and to increase therapeutic breadth. As antibody-based approaches are identified and advanced, promising small-molecule antivirals currently in clinical stage development should continue to be evaluated for filovirus diseases, with consideration of their added value in combination approaches with bundled supportive care, their penetration in tissues of interest, the absence of interaction with glycoprotein-based vaccines, and filoviral breadth. |Antibodies, Monoclonal/*therapeutic use[MESH] |Ebola Vaccines/*immunology[MESH] |Hemorrhagic Fever, Ebola/*prevention & control/*therapy[MESH] |Humans[MESH]Recent successes in therapeutics for Ebola virus disease: no time for (epmc).pdf DeepDyve Pubget Overpricing